Bionano Other Operating Expenses from 2010 to 2024
| BNGO Stock | USD 0.42 0.02 5.00% |
Other Operating Expenses | First Reported 2016-12-31 | Previous Quarter 35.9 M | Current Value 28.1 M | Quarterly Volatility 15 M |
Check Bionano Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bionano Genomics' main balance sheet or income statement drivers, such as Tax Provision of 65.1 K, Interest Income of 3.5 M or Depreciation And Amortization of 14.4 M, as well as many indicators such as Price To Sales Ratio of 1.7, Dividend Yield of 0.0 or PTB Ratio of 0.64. Bionano financial statements analysis is a perfect complement when working with Bionano Genomics Valuation or Volatility modules.
Bionano | Other Operating Expenses |
Latest Bionano Genomics' Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Bionano Genomics over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bionano Genomics. It is also known as Bionano Genomics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Bionano Genomics' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bionano Genomics' overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Bionano Other Operating Expenses Regression Statistics
| Arithmetic Mean | 63,851,164 | |
| Geometric Mean | 46,868,280 | |
| Coefficient Of Variation | 92.83 | |
| Mean Deviation | 47,872,066 | |
| Median | 32,119,340 | |
| Standard Deviation | 59,270,082 | |
| Sample Variance | 3512.9T | |
| Range | 156.4M | |
| R-Value | 0.80 | |
| Mean Square Error | 1336.9T | |
| R-Squared | 0.65 | |
| Significance | 0.0003 | |
| Slope | 10,657,146 | |
| Total Sum of Squares | 49181.2T |
Bionano Other Operating Expenses History
About Bionano Genomics Financial Statements
Bionano Genomics investors utilize fundamental indicators, such as Other Operating Expenses, to predict how Bionano Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 175.5 M | 184.3 M |
Pair Trading with Bionano Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bionano Stock
Moving against Bionano Stock
| 0.78 | VCYT | Veracyte | PairCorr |
| 0.69 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.56 | VERA | Vera Therapeutics | PairCorr |
| 0.55 | DNLI | Denali Therapeutics | PairCorr |
| 0.5 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Bionano Stock
When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:Check out the analysis of Bionano Genomics Correlation against competitors. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 9.89 | Revenue Per Share 0.749 | Quarterly Revenue Growth (0.10) | Return On Assets (0.33) | Return On Equity (1.38) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.